BioPharm Weekly News Roundup—Week of Sept. 22, 2025

Welcome to the BioPharm International® weekly news roundup for the week of Sept. 22, 2025. In this new video feature, the editors will highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

A 100% pharmaceutical tariff aims to boost US manufacturing, exempting companies, such as AstraZeneca and Eli Lilly and Company, that invest billions of dollars into domestic infrastructure.

Abzena, Revvity, and ProteoNic are collaborating on new AbZelectPRO cell line systems, accelerating biomanufacturing timelines and boosting therapeutic protein production yields.

BIO-Europe 2025, hosted by EBD Group and to be held in Vienna on Nov. 3–5, will gather 5700 attendees for critical discussions on biopharma investment, innovation, and strategic partnerships.

Enzene Biosciences opened its 80,000-square-foot Hopewell, NJ facility in early September 2025, aiming to be a “continuously innovative” development and manufacturing organization.

Integrated DNA Technologies launched Alt-R HDR Enhancer Protein to improve clustered regularly interspaced short palindromic repeats gene editing precision and homology-directed repair efficiency in difficult cell types.

Pfizer is acquiring Metsera for $4.9 billion to bolster its obesity therapeutic pipeline with next-generation oral and injectable incretin candidates.

Quantoom Biosciences and Memorial Sloan Kettering partnered to use Quantoom’s QCX-002 LNP technology for developing personalized RNA-based cancer therapies.

Lonza and RION partnered for current good manufacturing practice manufacturing to scale production of RION's platelet-derived exosome product, PEP, for clinical and commercial use.